The Department of Labor finalized a rule requiring PBMs to disclose compensation, rebates and spread payments to self-funded employer clients, starting July 2027. For plan sponsors, it gives visibility into PBM economics and sets up contract and audit conversations before the effective date.
The Department of Labor has finalized its PBM disclosure rule, moving forward PBM transparency requirements.
The Association for Accessible Medicines submitted comments on the Department of Labor's proposed PBM transparency and disclosure rule.
A Department of Labor regulation expected Thursday would require PBMs to disclose drug prices and drugmaker payments to self-insured employer clients, effective July.
A new federal rule will require drug intermediaries to disclose how they are paid.
A Politico report says Republican antitrust enforcers are the ones pursuing CVS, per the headline; page text was unavailable.
Pharmacies will receive $2.1 million from the state following a settlement with CVS Caremark.
The University of Kentucky has sued CVS over a dispute concerning drug revenue, according to a FOX 56 News headline.
The Hoboken City Council voted 7-2 to approve an $801,000 employer group Medicare Part D plan with Judi Rx.
Evernorth Holdings Inc. has filed a Form S-1 registration statement, according to a StreetInsider item; full filing text was unavailable.
Cigna Group's stock is heading into its earnings report following a dividend decision, according to a brief market preview.
Bloomberg reports that fewer US employees will have employer coverage for GLP-1 weight-loss drugs.
Commentary asks whether employers will use newly available visibility into what PBMs are paid, given the fee transparency now accessible to them.
Headline says large employer health plans will receive PBM rebates, but the article text was unavailable, so details are unconfirmed.
Employer GLP-1 coverage is reported to fall to 53%, with workers losing Wegovy or Zepbound coverage in 2027 weighing prices and appeals.
Employers are pulling back on GLP-1 coverage, and Andel and Novo Nordisk are offering a workaround for plan sponsors.
Andel is expanding beyond GLP-1 management with CenterWell Pharmacy to help employers lower high-cost drug spending.
Optum Rx announced it is expanding access to menopause care, according to the headline; the page text was unavailable for details.
Representative Jack Bergman introduced H.R. 10919, the Safety Net Provider Drug Pricing Protection Act, a bill addressing drug pricing for safety net providers.
Reps. Matsui and Mann introduced a bipartisan bill aimed at the 340B drug pricing program.
Five Massachusetts hospitals sued Eli Lilly, seeking to protect patient privacy and restore federally mandated 340B drug discounts.
IQVIA published findings on how large duplicate discounts are when 340B and Medicare Drug Price Negotiation (MFP) discounts overlap, the second part of its analysis.